Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The alternative pathway (AP) of complement activation is constitutively active and must be regulated by host proteins to prevent autologous tissue injury. Dysfunction of AP regulatory proteins has been linked to several human inflammatory disorders. Properdin is a positive regulator of AP complement activation that has been shown to extend the half-life of cell surface–bound C3 convertase C3bBb; it may also initiate AP complement activation. Here, we demonstrate a critical role for properdin in autologous tissue injury mediated by AP complement activation. We identified myeloid lineage cells as the principal source of plasma properdin by generating mice with global and tissue-specific knockout of Cfp (which encodes properdin) and by generating BM chimeric mice. Properdin deficiency rescued mice from AP complement–mediated embryonic lethality caused by deficiency of the membrane complement regulator Crry and markedly reduced disease severity in the K/BxN model of arthritis. Ab neutralization of properdin in WT mice similarly ameliorated arthritis development, whereas reconstitution of properdin-null mice with exogenous properdin restored arthritis sensitivity. These data implicate systemic properdin as a key contributor to AP complement–mediated injury and support its therapeutic targeting in complement-dependent human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficient in vivo manipulation of mouse genomic sequences at the zygote stage.
Lakso, M., Pichel, J. G., Gorman, J. R., Sauer, B., Okamoto, Y., Lee, E., Alt, F. W., & Westphal, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5860 · Cited by 1,125
Wirthmueller, U., Dewald, B., Thelen, M., Schäfer, M. K., Stover, C., Whaley, K., North, J., Eggleton, P., Reid, K. B., & Schwaeble, W. J. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.9.4444 · Cited by 156
Properdin: New roles in pattern recognition and target clearance
Kemper, C., & Hourcade, D. E. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.06.034 · Cited by 95
Cited by
Pathophysiology of rheumatoid arthritis
Cooles, F. A., & Isaacs, J. D. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834518a3 · Cited by 186
The complement system and adverse pregnancy outcomes
Regal, J. F., Gilbert, J. S., & Burwick, R. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.02.030 · Cited by 172
“Experiments demonstrated that animals deficient in C3, Factor B and properdin (Kimura et al., 2010) were protected from fetal loss in Crry knockout mice, whereas C4 or C5 deficient animals were not.”
BackgroundProperdin and factor h: Opposing players on the alternative complement pathway “see-saw”
Kouser, L., Abdul-Aziz, M., Nayak, A., Stover, C. M., Sim, R. B., & Kishore, U. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00093 · Cited by 91
“Release of properdin locally by leukocytes at the site of inflammation would activate the alternative pathway and aggravate tissue injury in the joint (Kimura et al., 2010).”
BackgroundRohrer, B., Coughlin, B., Kunchithapautham, K., Long, Q., Tomlinson, S., Takahashi, K., & Holers, V. M. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2010.12.016 · Cited by 62
“Properdin, which was thought to act only as a positive regulator of AP complement activation, has recently been shown to be able to initiate AP activation (see (Hourcade, 2008)) and has been shown to be involved in AP-mediated autologous tissue injury (Kimura et al., 2010).”
BackgroundToll-Like Receptor 4 Is a Regulator of Monocyte and Electroencephalographic Responses to Sleep Loss
Wisor, J. P., Clegern, W. C., & Schmidt, M. A. (2011) · Sleep · doi:10.5665/sleep.1274 · Cited by 54
Metadata
- Authors
- Kimura, Y., Zhou, L., Miwa, T., & Song, W.-C.
- Venue
- Journal of Clinical Investigation
- Published
- 2010-10-01
- Volume
- 120
- Issue
- 10
- Pages
- 3545-3554
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2155496945
- Cited by
- 73
- References
- 3
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.